(EN) The invention relates to new pharmaceutically active compounds of formula (I) or a salt thereof in which A is a 5-membered heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur, which are P2-purinoceptor 7-transmembrane (TM)G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.(FR) L'invention concerne de nouveaux composés actifs pharmaceutiquement de la formule (I) ou leur sel, formule dans laquelle A est un noyau hétérocyclique à 5 éléments contenant 1 à 3 hétéroatomes sélectionnés parmi l'azote, l'oxygène ou le soufre. Ces composés sont des antagonistes des récepteurs liés aux protéines G 7-transmembranaires(TM) P2-purinocepteurs. L'invention concerne des compositions contenant ces composés et leurs procédés de préparation.
This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.